These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34781869)

  • 1. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
    Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
    Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines and Nanosimilars: Looking for a New and Dynamic Regulatory "Astrolabe" Inspired System.
    Demetzos C; Kavatzikidou P; Pippa N; Stratakis E
    AAPS PharmSciTech; 2020 Jan; 21(2):65. PubMed ID: 31933006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.
    Halwani AA; Balkhi B; Alamoudi AA; Almozain NH; Alajmi AM; Noorwali A; Badr MY; Noor AO; Bagalagel A; Tawfik EA
    Saudi Pharm J; 2023 Aug; 31(8):101674. PubMed ID: 37448843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling the challenges of nanomedicines: are we ready?
    Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
    Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
    Agarwal V; Bajpai M; Sharma A
    Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
    Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
    Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.
    Parveen S; Sahoo SK
    Clin Pharmacokinet; 2006; 45(10):965-88. PubMed ID: 16984211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.